A RANKL G278R mutation causing osteopetrosis identifies a functional amino acid essential for trimer assembly in RANKL and TNF.
暂无分享,去创建一个
George Kollias | Georg Schett | Elias Eliopoulos | Eleni Douni | Vagelis Rinotas | G. Kollias | J. Penninger | E. Eliopoulos | J. Zwerina | G. Schett | E. Douni | Jochen Zwerina | Eleni Makrinou | Josef M Penninger | E. Makrinou | V. Rinotas
[1] S. Nishikawa,et al. The murine mutation osteopetrosis is in the coding region of the macrophage colony stimulating factor gene , 1990, Nature.
[2] E. Wagner,et al. Reaching a genetic and molecular understanding of skeletal development. , 2002, Developmental cell.
[3] S. M. Sims,et al. Regulation of cancer cell migration and bone metastasis by RANKL , 2006, Nature.
[4] D L Lacey,et al. RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[5] Akira Yamaguchi,et al. A TNF receptor loop peptide mimic blocks RANK ligand-induced signaling, bone resorption, and bone loss. , 2006, The Journal of clinical investigation.
[6] D L Lacey,et al. Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo. , 2000, The American journal of pathology.
[7] Claus Christiansen,et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. , 2009, The New England journal of medicine.
[8] W. Dougall,et al. RANK is essential for osteoclast and lymph node development. , 1999, Genes & development.
[9] K. Hirokawa,et al. Determination of three isoforms of the receptor activator of nuclear factor-kappaB ligand and their differential expression in bone and thymus. , 2001, Endocrinology.
[10] F. Saad,et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. , 2009, The New England journal of medicine.
[11] E. Wagner,et al. c-Fos: a key regulator of osteoclast-macrophage lineage determination and bone remodeling. , 1994, Science.
[12] M. Chen,et al. Site-directed mutational analysis of human tumor necrosis factor-alpha receptor binding site and structure-functional relationship. , 1992, The Journal of biological chemistry.
[13] H. Ochs,et al. Mutations of the CD40 ligand gene and its effect on CD40 ligand expression in patients with X-linked hyper IgM syndrome. , 1998, Blood.
[14] C. Goodnow,et al. Genome-wide ENU mutagenesis to reveal immune regulators. , 2001, Immunity.
[15] Klaus Schughart,et al. Genome-wide, large-scale production of mutant mice by ENU mutagenesis , 2000, Nature Genetics.
[16] D. Lacey,et al. The Osteoclast Differentiation Factor Osteoprotegerin-Ligand Is Essential for Mammary Gland Development , 2000, Cell.
[17] R. Dubose,et al. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function , 1997, Nature.
[18] W. Fiers,et al. Heterotrimers Formed by Tumor Necrosis Factors of Different Species or Muteins* , 2001, The Journal of Biological Chemistry.
[19] M. Widschwendter,et al. Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer , 2010, Nature.
[20] K Yano,et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[21] Y. Kadono,et al. Negative Regulation of Osteoclastogenesis by Ectodomain Shedding of Receptor Activator of NF-κB Ligand* , 2006, Journal of Biological Chemistry.
[22] Jongkeun Choi,et al. Structure-based development of a receptor activator of nuclear factor-κB ligand (RANKL) inhibitor peptide and molecular basis for osteopetrosis , 2010, Proceedings of the National Academy of Sciences.
[23] W. Dougall,et al. Mixed Metastatic Lung Cancer Lesions in Bone Are Inhibited by Noggin Overexpression and Rank:Fc Administration , 2006, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[24] S. Wysocki,et al. Cloning, Sequencing, and Functional Characterization of the Rat Homologue of Receptor Activator of NF‐κB Ligand , 2000 .
[25] T. Blundell,et al. Comparative protein modelling by satisfaction of spatial restraints. , 1993, Journal of molecular biology.
[26] N. Bishop,et al. Osteoclast-poor human osteopetrosis due to mutations in the gene encoding RANKL , 2007, Nature Genetics.
[27] Jingshan Ren,et al. The affinity of human RANK binding to its ligand RANKL. , 2009, Archives of biochemistry and biophysics.
[28] David L. Lacey,et al. Osteoclast differentiation and activation , 2003, Nature.
[29] V. Chapman,et al. Effects of ENU dosage on mouse strains , 2000, Mammalian Genome.
[30] J. Cornish,et al. Mutations within the TNF-like core domain of RANKL impair osteoclast differentiation and activation. , 2009, Molecular endocrinology.
[31] Hao Wu,et al. R/qtl: QTL Mapping in Experimental Crosses , 2003, Bioinform..
[32] Yongwon Choi,et al. Diverse roles of the tumor necrosis factor family member TRANCE in skeletal physiology revealed by TRANCE deficiency and partial rescue by a lymphocyte-expressed TRANCE transgene. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[33] Hao Sun,et al. Metabolic activation of a novel 3-substituted indole-containing TNF-alpha inhibitor: dehydrogenation and inactivation of CYP3A4. , 2008, Chemical research in toxicology.
[34] J. Penninger,et al. RANK(L) as a key target for controlling bone loss. , 2009, Advances in experimental medicine and biology.
[35] Brian R. Wong,et al. TRANCE Is a Novel Ligand of the Tumor Necrosis Factor Receptor Family That Activates c-Jun N-terminal Kinase in T Cells* , 1997, The Journal of Biological Chemistry.
[36] Jun Wang,et al. Small-Molecule Inhibition of TNF-α , 2005, Science.
[37] S. Wysocki,et al. Cloning, sequencing, and functional characterization of the rat homologue of receptor activator of NF-kappaB ligand. , 2000, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[38] G. Kollias,et al. Functional genetic and genomic analysis of modeled arthritis. , 2007, Advances in experimental medicine and biology.
[39] R. Owens,et al. Structural and Functional Insights of RANKL–RANK Interaction and Signaling , 2010, The Journal of Immunology.
[40] S. Morony,et al. osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. , 1998, Genes & development.
[41] C. Nelson,et al. Crystal structure of the TRANCE/RANKL cytokine reveals determinants of receptor-ligand specificity. , 2001, The Journal of clinical investigation.
[42] J. Penninger,et al. RANK signals from CD4+3− inducer cells regulate development of Aire-expressing epithelial cells in the thymic medulla , 2007, The Journal of Experimental Medicine.
[43] A. Whitty,et al. Small-molecule inhibition of TNF-alpha. , 2005, Science.
[44] Tadashi Hata,et al. Crystal Structure of the Extracellular Domain of Mouse RANK Ligand at 2.2-Å Resolution* , 2002, The Journal of Biological Chemistry.
[45] H. Takayanagi. Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems , 2007, Nature Reviews Immunology.
[46] B. Beutler,et al. ENU mutagenesis in mice. , 2008, Methods in molecular biology.
[47] Steven W. Martin,et al. A Phase I study of AMGN‐0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases , 2003, Cancer.
[48] T. Shinki,et al. Vitamin D and bone , 2003, Journal of cellular biochemistry.
[49] Sujay K. Singh,et al. Inhibition of RANKL-mediated osteoclast differentiation by selective TRAF6 decoy peptides. , 2007, Biochemical and biophysical research communications.
[50] Jianpeng Ma,et al. CHARMM: The biomolecular simulation program , 2009, J. Comput. Chem..
[51] S. Morony,et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis , 1999, Nature.
[52] D. Lacey,et al. Osteoprotegerin Ligand Is a Cytokine that Regulates Osteoclast Differentiation and Activation , 1998, Cell.
[53] A. Haeseler,et al. Central control of fever and female body temperature by RANKL/RANK , 2009, Nature.